基本信息
views: 240
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Larsen has made seminal contributions to the investigation of the immunologic mechanisms of transplant rejection and immunologic tolerance and is an internationally recognized leader in kidney and pancreas transplantation. He has been funded continuously by the NIH since 1996. The recipient of a prestigious NIH MERIT award, he has directed program project grants, center awards, and multi-institutional consortia.
With his long-time collaborator Dr. Thomas Pearson, Dr. Larsen initiated a transplant immunology research program that played a pivotal role in developing a new class of immunosuppressive drugs known as costimulation blockers. One such drug is belatacept, which Dr. Larsen, Dr. Pearson, and researchers at Bristol Myers Squibb began developing in the 1990s as a less toxic alternative to standard immunosuppressants. In 2011, the FDA approved belatacept in the form of the drug Nulojix for kidney transplant recipients. In 2015, the BENEFIT study, which was initiated in 2006 and led by Dr. Larsen and UCSF transplant specialist Dr. Flavio Vincenti, conclusively showed that belatacept had a better record of patient and organ survival than a calcineurin inhibitor.
With his long-time collaborator Dr. Thomas Pearson, Dr. Larsen initiated a transplant immunology research program that played a pivotal role in developing a new class of immunosuppressive drugs known as costimulation blockers. One such drug is belatacept, which Dr. Larsen, Dr. Pearson, and researchers at Bristol Myers Squibb began developing in the 1990s as a less toxic alternative to standard immunosuppressants. In 2011, the FDA approved belatacept in the form of the drug Nulojix for kidney transplant recipients. In 2015, the BENEFIT study, which was initiated in 2006 and led by Dr. Larsen and UCSF transplant specialist Dr. Flavio Vincenti, conclusively showed that belatacept had a better record of patient and organ survival than a calcineurin inhibitor.
Research Interests
Papers共 720 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Frontiers in transplantation (2024): 1280993-1280993
Frontiers in immunology (2024): 1436233-1436233
Emily M. Eichenberger, Maja Wichhart Donzo,Rebecca Anderson,Geeta Karadkhele,Stephanie M. Pouch,Christian P. Larsen
CLINICAL TRANSPLANTATIONno. 3 (2024): e15279-e15279
Ahmed Babiker,Geeta Karadkhele,Andrei Bombin, Rockford Watkins,Chad Robichaux,Gillian Smith,Vivek B. Beechar, Danielle B. Steed, Jesse T. Jacobs,Timothy D. Read,Sarah Satola,Christian P. Larsen,
Emily M Eichenberger,Wairimu Magua, Joseph B Rickert,Geeta Karadkhele, Mohammad Kazem Fallahzadeh,Payaswini Vasanth,Christian Larsen
Transplant infectious disease : an official journal of the Transplantation Societypp.e14298-e14298, (2024)
AMERICAN JOURNAL OF TRANSPLANTATIONno. 6 (2023): S1075-S1076
Cited0Views0Bibtex
0
0
Load More
Author Statistics
#Papers: 716
#Citation: 33406
H-Index: 88
G-Index: 174
Sociability: 8
Diversity: 0
Activity: 2
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn